235 related articles for article (PubMed ID: 32510723)
1. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan.
Hamada Y; Ueda T; Miyazaki Y; Nakajima K; Fukunaga K; Miyazaki T; Nakada-Motokawa N; Nagao M; Kawamura H; Shigemi A; Ebihara F; Kimura T; Ikegame K; Uchino M; Ikeuchi H; Takesue Y
Mycoses; 2020 Aug; 63(8):779-786. PubMed ID: 32510723
[TBL] [Abstract][Full Text] [Related]
2. Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients.
Hanai Y; Ueda T; Hamada Y; Oda K; Takahashi Y; Nakajima K; Miyazaki Y; Kiriyama M; Uekusa S; Matsuo K; Matsumoto K; Kimura T; Takesue Y
Mycoses; 2023 Dec; 66(12):1035-1044. PubMed ID: 37584173
[TBL] [Abstract][Full Text] [Related]
3. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
[TBL] [Abstract][Full Text] [Related]
4. Development of a therapeutic drug-monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study.
Kato H; Umemura T; Hagihara M; Shiota A; Asai N; Hamada Y; Mikamo H; Iwamoto T
Br J Clin Pharmacol; 2024 May; 90(5):1222-1230. PubMed ID: 38320604
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
[TBL] [Abstract][Full Text] [Related]
6. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study.
Wang T; Miao L; Shao H; Wei X; Yan M; Zuo X; Zhang J; Hai X; Fan G; Wang W; Hu L; Zhou J; Zhao Y; Xie Y; Wang J; Guo S; Jin L; Li H; Liu H; Wang Q; Chen J; Li S; Dong Y
Int J Antimicrob Agents; 2022; 60(5-6):106692. PubMed ID: 36372345
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
[TBL] [Abstract][Full Text] [Related]
8. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
[TBL] [Abstract][Full Text] [Related]
9. Impact of dose adaptations following voriconazole therapeutic drug monitoring in pediatric patients.
Lempers VJ; Meuwese E; Mavinkurve-Groothuis AM; Henriet S; van der Sluis IM; Hanff LM; Warris A; Koch BCP; Brüggemann RJ
Med Mycol; 2019 Nov; 57(8):937-943. PubMed ID: 30759261
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin
.
Hirata A; Noto K; Ota R; Yokoyama S; Hosomi K; Takada M; Matsuoka H
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):135-143. PubMed ID: 30686290
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
[TBL] [Abstract][Full Text] [Related]
13. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
14. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
Jin H; Wang T; Falcione BA; Olsen KM; Chen K; Tang H; Hui J; Zhai S
J Antimicrob Chemother; 2016 Jul; 71(7):1772-85. PubMed ID: 26968880
[TBL] [Abstract][Full Text] [Related]
15. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
[TBL] [Abstract][Full Text] [Related]
16. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
Gautier-Veyret E; Truffot A; Bailly S; Fonrose X; Thiebaut-Bertrand A; Tonini J; Cahn JY; Stanke-Labesque F
Fundam Clin Pharmacol; 2019 Apr; 33(2):232-238. PubMed ID: 30306637
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics.
Chiang YH; Cheng CN; Chuang PJ; Chen YC; Chen YJ; Kuo CH; Lin SW; Chang LC
Int J Antimicrob Agents; 2024 Jan; 63(1):107028. PubMed ID: 37931850
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
[TBL] [Abstract][Full Text] [Related]
19. [Factors Influencing and Adverse Reactions of Voriconazole Clearance in Patients with Hematological Diseases].
Huang HG; Wang HL; Lin YK; Yi YD; Liu M; Dong JL; Liu JM; Chen F; Deng TY; Hu S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):562-567. PubMed ID: 37096534
[TBL] [Abstract][Full Text] [Related]
20. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
